$ARMP
Armata Pharmaceuticals, Inc.

2018 Q4 Form 10-Q Financial Statement

#000114420418058340 Filed on November 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q4
Revenue $0.00 $0.00 $20.00K
YoY Change -100.0% -100.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.475M $1.276M $1.300M
YoY Change 13.46% -20.75% -15.58%
% of Gross Profit
Research & Development $1.375M $361.0K $1.090M
YoY Change 26.15% -143.49% 36.25%
% of Gross Profit
Depreciation & Amortization $90.00K $68.00K $90.00K
YoY Change 0.0% -24.44% -10.0%
% of Gross Profit
Operating Expenses $2.850M $1.637M $2.390M
YoY Change 19.25% 108.8% 2.14%
Operating Profit -$1.637M
YoY Change 119.44%
Interest Expense $132.0K $31.00K $10.00K
YoY Change 1220.0% -177.5% -99.53%
% of Operating Profit
Other Income/Expense, Net $0.00 $31.00K $0.00
YoY Change -193.94% -100.0%
Pretax Income -$4.648M -$1.606M -$2.350M
YoY Change 97.79% 106.16% -76.64%
Income Tax -$328.0K $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.320M -$1.606M -$2.350M
YoY Change 83.83% 106.16% -75.26%
Net Earnings / Revenue -11750.0%
Basic Earnings Per Share -$0.10
Diluted Earnings Per Share -$2.038M -$0.10 -$3.456M
COMMON SHARES
Basic Shares Outstanding 32.29M 16.47M
Diluted Shares Outstanding 16.50M

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.157M $4.499M $5.130M
YoY Change 59.01% -41.8% -10.16%
Cash & Equivalents $8.157M $4.499M $5.132M
Short-Term Investments
Other Short-Term Assets $251.0K $615.0K $250.0K
YoY Change 0.4% 136.54% -58.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $8.408M $5.114M $5.385M
YoY Change 56.14% -35.99% -14.66%
LONG-TERM ASSETS
Property, Plant & Equipment $503.0K $591.0K $816.0K
YoY Change -38.36% -30.47% -23.74%
Goodwill
YoY Change
Intangibles $2.731M $4.661M $4.661M
YoY Change -41.41%
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change
Total Long-Term Assets $3.479M $5.505M $5.753M
YoY Change -39.53% -4.92% -51.41%
TOTAL ASSETS
Total Short-Term Assets $8.408M $5.114M $5.385M
Total Long-Term Assets $3.479M $5.505M $5.753M
Total Assets $11.89M $10.62M $11.14M
YoY Change 6.72% -22.94% -38.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $729.0K $714.0K $578.0K
YoY Change 26.12% -24.84% -78.91%
Accrued Expenses $1.805M $1.751M $1.390M
YoY Change 29.86% 52.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.572M $2.465M $1.968M
YoY Change 30.69% -0.6% -44.41%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $22.00K $154.0K $290.0K
YoY Change -92.41% -61.5% -88.11%
Total Long-Term Liabilities $22.00K $154.0K $290.0K
YoY Change -92.41% -61.5% -88.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.572M $2.465M $1.968M
Total Long-Term Liabilities $22.00K $154.0K $290.0K
Total Liabilities $3.413M $3.766M $3.407M
YoY Change 0.18% -6.32% -59.58%
SHAREHOLDERS EQUITY
Retained Earnings -$406.3M -$402.0M -$394.2M
YoY Change 3.07%
Common Stock $323.0K $165.0K $95.00K
YoY Change 240.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.474M $6.853M $7.731M
YoY Change
Total Liabilities & Shareholders Equity $11.89M $10.62M $11.14M
YoY Change 6.72% -22.94% -38.63%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q4
OPERATING ACTIVITIES
Net Income -$4.320M -$1.606M -$2.350M
YoY Change 83.83% 106.16% -75.26%
Depreciation, Depletion And Amortization $90.00K $68.00K $90.00K
YoY Change 0.0% -24.44% -10.0%
Cash From Operating Activities -$2.428M -$1.244M -$2.370M
YoY Change 2.45% 110.85% 58.0%
INVESTING ACTIVITIES
Capital Expenditures -$3.000K -$11.00K -$20.00K
YoY Change -85.0% -63.33% 100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$3.000K -$11.00K -$20.00K
YoY Change -85.0% -63.33% 100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.089M -48.00K -210.0K
YoY Change -2999.52% -92.13% -106.44%
NET CHANGE
Cash From Operating Activities -2.428M -1.244M -2.370M
Cash From Investing Activities -3.000K -11.00K -20.00K
Cash From Financing Activities 6.089M -48.00K -210.0K
Net Change In Cash 3.658M -1.303M -2.600M
YoY Change -240.69% 5.93% -248.57%
FREE CASH FLOW
Cash From Operating Activities -$2.428M -$1.244M -$2.370M
Capital Expenditures -$3.000K -$11.00K -$20.00K
Free Cash Flow -$2.425M -$1.233M -$2.350M
YoY Change 3.19% 120.18% 57.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
aphb Offering Costs Included In Accounts Payable
OfferingCostsIncludedInAccountsPayable
277000
CY2018Q1 aphb Proceeds From Equity Offerings Gross
ProceedsFromEquityOfferingsGross
4000000
CY2018Q1 aphb Proceeds From Equity Offerings Gross
ProceedsFromEquityOfferingsGross
3000000
aphb Proceeds From Sale And Exercise Of Warrants
ProceedsFromSaleAndExerciseOfWarrants
9353000
aphb Proceeds From Sale And Exercise Of Warrants
ProceedsFromSaleAndExerciseOfWarrants
6159000
CY2017Q3 aphb Research And Development Benefit
ResearchAndDevelopmentBenefit
829000
aphb Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Ii
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi
P8Y3M11D
aphb Shares Issued Pursuant To Agreement Fair Value
SharesIssuedPursuantToAgreementFairValue
519000
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
408684000
CY2018Q3 us-gaap Assets
Assets
10619000
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
165000
CY2018Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1147000
CY2017Q4 us-gaap Liabilities
Liabilities
3407000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11138000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10619000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2465000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-401996000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
6853000
aphb Warrants Exercised During Period
WarrantsExercisedDuringPeriod
217400
aphb Warrants Expired During Period
WarrantsExpiredDuringPeriod
19691
CY2018Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.76
CY2018Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
8294827
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000921114
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32293308
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Registrant Name
EntityRegistrantName
AmpliPhi Biosciences Corp
dei Trading Symbol
TradingSymbol
APHB
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
578000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
714000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1390000
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1751000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
401842000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
568000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
98000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
366000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
120000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
23000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
23000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9872031
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10352195
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9443991
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9275493
us-gaap Asset Impairment Charges
AssetImpairmentCharges
5800000
CY2017Q4 us-gaap Assets
Assets
11138000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
5385000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
5114000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5711000
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7725000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5132000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4499000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2014000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-633000
CY2018Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9938290
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
67000000
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
67000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9498928
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16468308
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9498928
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16468308
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
95000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1302000
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1147000
us-gaap Depreciation
Depreciation
255000
us-gaap Depreciation
Depreciation
268000
CY2017Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
292000
CY2018Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
154000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1997000
CY2017Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-37000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-46000
CY2018Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
31000
CY2017Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
292000
CY2018Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
154000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.97
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.18
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2018Q3 us-gaap Employee Stock Ownership Plan Esop Number Of Committed To Be Released Shares
EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares
47172
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
184000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7744000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1637000
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
276000
CY2018Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
253000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6295000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1613000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4227000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1276000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11788000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-779000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7790000
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1606000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1302000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-595000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
218000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-370000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
85000
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4661000
CY2018Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4661000
CY2018Q3 us-gaap Liabilities
Liabilities
3766000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1968000
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
46000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
95000
CY2017Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
38000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8877000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6362000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-40000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6823000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6954000
us-gaap Net Income Loss
NetIncomeLoss
-10486000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-779000
us-gaap Net Income Loss
NetIncomeLoss
-7790000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-1606000
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-12032000
CY2017Q3 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-779000
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-7790000
CY2018Q3 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-1627000
us-gaap Operating Expenses
OperatingExpenses
13886000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
784000
us-gaap Operating Expenses
OperatingExpenses
7744000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
1637000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13791000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-746000
us-gaap Other Noncash Expense
OtherNoncashExpense
22000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
6000
CY2017Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
4000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2003000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-33000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-46000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
31000
us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
5800000
CY2017Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1200000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
40000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
41000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
253000
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
615000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
5000
CY2017Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
9400000
CY2018Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3400000
CY2018Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2800000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
31000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
198000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
816000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
591000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
510000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1791000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3517000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
361000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.08
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M23D
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-394206000
CY2017Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
2584085
CY2018Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
4000000
CY2018Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
2743640
CY2018Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.00
CY2018Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.10
us-gaap Share Based Compensation
ShareBasedCompensation
568000
us-gaap Share Based Compensation
ShareBasedCompensation
366000
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
39000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
361773
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.20
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y9M7D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3201
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
36500
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
118000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1115865
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1149164
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.17
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
90000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
864051
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.80
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y11D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.02
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.20
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
7731000
us-gaap Use Of Estimates
UseOfEstimates
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Use of Estimates</font> </p> <p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font> </p> <p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#x2019;s estimates.</font> </p> <p><font size="1"> </font></p> </div> </div>
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5518847
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8874813
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15418146
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16496957
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5326139
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8874813
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15418146
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16468308

Files In Submission

Name View Source Status
0001144204-18-058340-index-headers.html Edgar Link pending
0001144204-18-058340-index.html Edgar Link pending
0001144204-18-058340.txt Edgar Link pending
0001144204-18-058340-xbrl.zip Edgar Link pending
aphb-20180930.xml Edgar Link completed
aphb-20180930.xsd Edgar Link pending
aphb-20180930_cal.xml Edgar Link unprocessable
aphb-20180930_def.xml Edgar Link unprocessable
aphb-20180930_lab.xml Edgar Link unprocessable
aphb-20180930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv505699_10q.htm Edgar Link pending
tv505699_ex3-2.htm Edgar Link pending
tv505699_ex31-1.htm Edgar Link pending
tv505699_ex31-2.htm Edgar Link pending
tv505699_ex32-1.htm Edgar Link pending
tv505699_ex32-2.htm Edgar Link pending